When rare autoimmune neuromuscular trials stall, Leapcure delivers. From a Myasthenia Gravis rescue to a Phase 3 dermatomyositis study, we contribute the majority of enrollment.

Leapcure has recruited across Myasthenia Gravis, dermatomyositis, and CIDP and related inflammatory neuropathies, reaching small, dispersed communities through trusted advocacy and a dedicated Patient Success team. On a Phase 2 MG rescue we delivered 8 of the final 10 participants; on a Phase 3 dermatomyositis study we enrolled 13 patients, with four sites enrolling only Leapcure-referred patients.

Talk to our teamSee how it works →
8 of 10
Final participants delivered
on a Phase 2 MG rescue
13
Enrolled
on a Phase 3 dermatomyositis study
70%
Avg enrollment contribution
on Phase 2 rare autoimmune programs
30+
Advocacy partners engaged
in each disease community

Understanding Rare Autoimmune Neuromuscular Disease as a Clinical Trial Area

Rare autoimmune neuromuscular diseases are conditions in which the immune system attacks different parts of the neuromuscular system: the neuromuscular junction in Myasthenia Gravis, the muscle in dermatomyositis and other inflammatory myopathies, and the peripheral nerves in CIDP (chronic inflammatory demyelinating polyneuropathy) and related inflammatory neuropathies. They are distinct diseases that share a profile: each is rare, each is dispersed, and each depends on a small, tight-knit patient community.

Myasthenia Gravis has a US prevalence of about 37 per 100,000, roughly 75,000 to 100,000 people (Neurology, 2023; US claims analyses, 2024). CIDP has a US prevalence of about 8.9 per 100,000 (Frontiers in Neurology, 2025). Dermatomyositis is a rare inflammatory myopathy with prevalence in the single digits per 100,000. Because these populations are small, dispersed, and community-dependent, with complex, heterogeneous eligibility, generic recruitment underperforms and advocacy-led recruitment works. Reaching enough eligible patients also means reaching them globally, across many regions, for what are tiny populations in any one place.

Leapcure recruits across the full rare autoimmune neuromuscular spectrum, junction, muscle, and nerve, reaching these communities through the advocacy organizations patients already trust and a dedicated Patient Success team, and contributing the majority of enrollment. We have delivered across three different autoimmune neuromuscular targets: on a Phase 2 Myasthenia Gravis rescue we delivered 8 of the final 10 participants; on a Phase 3 dermatomyositis study we enrolled 13 patients, with four sites relying only on Leapcure referrals; and across the CIDP and inflammatory-neuropathy community we hold established global advocacy relationships. Across rare autoimmune programs our enrollment contribution averages about 60 percent on Phase 1, about 70 percent on Phase 2, and about 40 percent on Phase 3.

The Challenge

Rare autoimmune neuromuscular trials are hard for the same reasons across the spectrum: tiny, dispersed populations, complex eligibility, and patients who are reached only through the communities they trust.

These are distinct diseases, each rare and dispersed

Myasthenia Gravis affects the neuromuscular junction, dermatomyositis the muscle, and CIDP the peripheral nerves. Each is a separate disease with its own community, and each is small: MG prevalence is about 37 per 100,000, CIDP about 8.9 per 100,000, and dermatomyositis in the single digits. Reaching enough eligible patients means reaching them across many regions at once.

Leapcure has delivered across all three targets, junction, muscle, and nerve, with named advocacy relationships in each community.

Patients are reached through communities, not list buys

Small, tight-knit patient communities gather in disease-specific advocacy organizations they already trust. Cold digital and purchased lists do not reach them. Recruitment works when research reaches patients through the voices they already rely on, in each separate community.

30+ advocacy partners are engaged in each disease community, and on a Phase 2 MG rescue our 30+ MG partners were mobilizable in two days.

Eligibility is complex and heterogeneous

Each condition carries complex, heterogeneous eligibility, and patients vary widely in presentation and history. Generic campaigns surface patients who fail screening, spending scarce specialist-site time on people the protocol cannot use. Confirming fit before referral is what protects sites.

Real human conversations plus an in-house clinical-eligibility review mean patients are pre-qualified and documentation-ready before any site referral.

In small populations, you carry the majority of enrollment

When the eligible pool is tiny, a recruiter either contributes most of the enrollment or the study stalls. The question a sponsor should ask is how much of enrollment a partner actually carries in these populations, not how many referrals they generate.

Across rare autoimmune programs, Leapcure's enrollment contribution averages about 60% on Phase 1, about 70% on Phase 2, and about 40% on Phase 3.

How Leapcure recruits across the rare autoimmune neuromuscular spectrum

We activate the trusted community in each disease, pre-screen for complex eligibility with real human conversations and a clinical review, and support each patient from first contact through enrollment.

1

Activate the trusted community in each disease

We engage named advocacy anchors across Myasthenia Gravis, dermatomyositis, and the CIDP and inflammatory-neuropathy community, with 30+ advocacy partners in each, alongside precision digital mapped to your eligibility and geographies. Content is co-developed so research reaches patients through sources they already trust.

2

Pre-screen for complex eligibility before referral

Each patient is engaged through real human conversations, not automated screening, plus an in-house clinical-eligibility review, so patients are pre-qualified and documentation-ready before any site referral. Sites conduct official screening; we make sure the patients who arrive are eligible and prepared.

3

Support each patient through enrollment

A dedicated Patient Success Coordinator supports each patient from first contact through enrollment, reducing coordinator burden and screen fails. In small, dispersed populations, this continuity is how we carry the majority of enrollment and keep stalled studies moving.

Delivered across the spectrum: a Myasthenia Gravis rescue and a Phase 3 dermatomyositis study where four sites relied only on our referrals.

Challenge Context

Programs

A Phase 2 Myasthenia Gravis rescue (neuromuscular junction) and a Phase 3 dermatomyositis study (muscle)

Challenge

A stalled MG study that needed its final participants, and a Phase 3 dermatomyositis study facing site-engagement, medical-record, and patient-travel challenges in a tiny population.

CIDP and inflammatory neuropathy

Established global advocacy relationships across the inflammatory-neuropathy community, with co-developed partnership content that reaches patients through trusted voices.

Results & Metrics

Myasthenia Gravis: Rescue Delivery

Brought in to rescue a stalled Phase 2 study, Leapcure delivered 8 of the final 10 participants in the closing months, preventing further delays.

Myasthenia Gravis: Reach and Readiness

530+ patients pre-screened and 220 assigned to sites, with 30+ MG advocacy partners mobilizable in two days, supporting 10 active sites.

Dermatomyositis: Enrollment and Site Penetration

13 patients enrolled, about 43 percent of US enrollments during the scope; 7 of 9 sites enrolled Leapcure patients and 4 sites enrolled only Leapcure-referred patients, with 30+ myositis advocacy partners driving the majority of enrollment.

Average enrollment contribution

Across rare autoimmune programs, Leapcure contributes about 60 percent of enrollment on Phase 1, about 70 percent on Phase 2, and about 40 percent on Phase 3.

Four channels. Built for the rare autoimmune neuromuscular spectrum.

Leapcure reaches these small, dispersed communities through trusted advocacy in each disease, real human pre-screening, proven enrollment delivery, and answer-engine visibility delivered to your trial.

Channel 1: Advocacy across three communities

  • •Myasthenia Gravis: Conquer MG and the Myasthenia Gravis Foundation of America.
  • •Dermatomyositis and myositis: Myositis Support and Understanding and the Autoimmune Association. CIDP and inflammatory neuropathy: the GBS|CIDP Foundation International and the Neuropathy Action Foundation. Across rare disease: the National Organization for Rare Disorders (NORD).
  • •30+ advocacy partners are engaged in each disease community, active and co-developed, not list purchases.

Channel 2: Patient Success and human pre-screening

  • •Real human conversations, not automated screening, plus an in-house clinical-eligibility review, so patients are pre-qualified and documentation-ready before any site referral.
  • •A dedicated Patient Success Coordinator supports each patient from first contact through enrollment.
  • •This reduces coordinator burden and screen fails on specialized, scarce sites.

Channel 3: Proven enrollment delivery

  • •From a Myasthenia Gravis rescue to a Phase 3 dermatomyositis study where four sites relied only on our referrals, we deliver when trials stall.
  • •Across rare autoimmune programs our enrollment contribution averages about 60 percent on Phase 1, about 70 percent on Phase 2, and about 40 percent on Phase 3.
  • •In tiny populations, carrying the majority of enrollment is the difference between a study that finishes and one that stalls.

Channel 4: Answer-engine and AI-search visibility

  • •Patients increasingly ask ChatGPT, Perplexity, and Google's AI Overview which trials they may be eligible for. We make your trial's information genuinely retrievable for those engines.
  • •We do this with crawlable, factually rich content, cited sources, and presence in the advocacy and community sources AI engines actually cite, not schema tricks or content written for machines.
  • •Because AI engines cite trusted third-party sources more often than any single brand domain, our advocacy partnerships across each community and our ClinicalTrials.gov presence are the structural advantage we bring to your trial.

Named advocacy anchors across all three communities

Leapcure's partnerships are active and co-developed, not list purchases, with named anchors in each disease community and 30+ advocacy partners engaged per community. Full per-community partner lists are available, and we name only confirmed partners.

Conquer MG

Myasthenia Gravis patient organization and a trusted referral channel in the MG community

Myasthenia Gravis Foundation of America

Leading national Myasthenia Gravis patient and research organization

Myositis Support and Understanding

Patient-led organization serving the dermatomyositis and broader myositis community

Autoimmune Association

National autoimmune advocacy organization reaching the broader inflammatory-myopathy population

GBS|CIDP Foundation International

Leading patient organization for CIDP and related inflammatory neuropathies

Neuropathy Action Foundation

Patient advocacy organization for the inflammatory-neuropathy community

National Organization for Rare Disorders (NORD)

Leading US rare-disease advocacy organization and credibility anchor across all three communities

Living with a rare autoimmune neuromuscular condition? A clinical trial may be an option to explore.

If you are living with Myasthenia Gravis, dermatomyositis, CIDP, or a related inflammatory neuropathy, or caring for someone who is, a clinical trial may offer access to investigational treatments alongside your existing care, never instead of it. We know these are rare, complex conditions, and we will never pressure you. Leapcure's team answers your questions honestly, explains what a trial involves, and supports you step by step.

Explore trials in your condition community
Leapcure kangaroo mascot

Leapcure has delivered across the rare autoimmune neuromuscular spectrum, junction, muscle, and nerve, from a Myasthenia Gravis rescue to a Phase 3 dermatomyositis study where four sites relied only on our referrals, with named advocacy relationships in each community and a Patient Success team that carries the majority of enrollment. We reach these small, dispersed communities through the organizations patients already trust and deliver enrollment-ready patients to your sites. We can mobilize quickly.

Talk to our team